Mesenchymal stromal cells and the innate immune response

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 140-146

  Le Blanc, Katarina ^a   Davies, Lindsay C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immunomodulation; Inflammation; Innate immunity; Mesenchymal stromal cells

Indexed keywords

COMPLEMENT; CYTOKINE; AUTACOID;

ARTICLE; CELL INTERACTION; CELL PROLIFERATION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; ANIMAL; BIOLOGICAL MODEL; CELL COMMUNICATION; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS); TUMOR MICROENVIRONMENT;

ANIMALS; CELL COMMUNICATION; CELLULAR MICROENVIRONMENT; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MESENCHYMAL STROMAL CELLS; MODELS, IMMUNOLOGICAL;

EID: 84949626181     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.05.004     Document Type: Article

References (69)

1. Ozato K., Tsujimura H., Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 2002, 66-68. 70, 72 passim.
2. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 2010, 5:e10088.
3. Diaz-Flores L., Gutierrez R., Madrid J.F., Varela H., Valladares F., Acosta E., et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 2009, 24:909-969.
4. Hughes P.D., Cohney S.J. Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr. Opin. Organ Transpl. 2011, 16:425-433.
5. Li Y., Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood 2012, 120:3436-3443.
6. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
7. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.
8. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 2012, 12:383-396.
9. Moll G., Jitschin R., von Bahr L., Rasmusson-Duprez I., Sundberg B., Lonnies L., et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS ONE 2011, 6:e21703.
10. Tu Z., Li Q., Bu H., Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 2010, 19:1803-1809.
11. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O.H.L.A. expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 2003, 31:890-896.
12. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
13. Tomchuck S.L., Zwezdaryk K.J., Coffelt S.B., Waterman R.S., Danka E.S., Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008, 26:99-107.
14. Ulivi V., Tasso R., Cancedda R., Descalzi F. Mesenchymal stem cell paracrine activity is modulated by platelet lysate: induction of an inflammatory response and secretion of factors maintaining macrophages in a proinflammatory phenotype. Stem Cells Dev. 2014, 23:1858-1869.
15. Chao Y.H., Wu H.P., Wu K.H., Tsai Y.G., Peng C.T., Lin K.C., et al. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLOS ONE 2014, 9:e110338.
16. Luo C.J., Zhang F.J., Zhang L., Geng Y.Q., Li Q.G., Hong Q., et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014, 41:123-129.
17. Weiss S.J. Tissue destruction by neutrophils. N. Eng. J. Med. 1989, 320:365-376.
18. Lundahl J., Jacobson S.H., Paulsson J.M. IL-8 from local subcutaneous wounds regulates CD11b activation. Scand. J. Immunol. 2012, 75:419-425.
19. Hall S.R., Tsoyi K., Ith B., Padera R.F., Lederer J.A., Wang Z., et al. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells 2013, 31:397-407.
20. Luo H.R., Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. Am. J. Hematol. 2008, 83:288-295.
21. Raffaghello L., Bianchi G., Bertolotto M., Montecucco F., Busca A., Dallegri F., et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008, 26:151-162.
22. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556.
23. Sehmi R., Howie K., Sutherland D.R., Schragge W., O'Byrne P.M., Denburg J.A. Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects. Am. J. Respir. Cell Mol. Biol. 1996, 15:645-655.
24. Nemeth K., Wilson T., Rada B., Parmelee A., Mayer B., Buzas E., et al. Characterization and function of histamine receptors in human bone marrow stromal cells. Stem Cells 2012, 30:222-231.
25. Nemeth K., Keane-Myers A., Brown J.M., Metcalfe D.D., Gorham J.D., Bundoc V.G., et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5652-5657.
26. Cho K.S., Park H.K., Park H.Y., Jung J.S., Jeon S.G., Kim Y.K., et al. IFATS collection: immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells 2009, 27:259-265.
27. Brown J.M., Nemeth K., Kushnir-Sukhov N.M., Metcalfe D.D., Mezey E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin. Exp. Allergy 2011, 41:526-534.
28. Kim H., Yun J., Shin T., Lee S., Lee B., Yu K., et al. Human umbilical cord blood mesenchymal stem cell-derived PGE and TGF-beta1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells 2014.
29. Su W.R., Zhang Q.Z., Shi S.H., Nguyen A.L., Le A.D. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells 2011, 29:1849-1860.
30. Su W., Wan Q., Huang J., Han L., Chen X., Chen G., et al. Culture medium from TNF-alpha-stimulated mesenchymal stem cells attenuates allergic conjunctivitis through multiple antiallergic mechanisms. J. Allergy Clin. Immunol. 2015.
31. Jacobs R., Stoll M., Stratmann G., Leo R., Link H., Schmidt R.E. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992, 79:3239-3244.
32. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
33. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 1996, 14:619-648.
34. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
35. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
36. Chatterjee D., Marquardt N., Tufa D.M., Hatlapatka T., Hass R., Kasper C., et al. Human umbilical cord-derived mesenchymal stem cells utilize activin-A to suppress interferon-gamma production by natural killer cells. Front. Immunol. 2014, 5:662.
37. Noone C., Kihm A., English K., O'Dea S., Mahon B.P. IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 2013, 22:3003-3014.
38. Gotherstrom C., Lundqvist A., Duprez I.R., Childs R., Berg L., le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 2011, 13:269-278.
39. Dubois B., Bridon J.M., Fayette J., Barthelemy C., Banchereau J., Caux C., et al. Dendritic cells directly modulate B cell growth and differentiation. J. Leukoc. Biol. 1999, 66:224-230.
40. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 2002, 195:327-333.
41. Zhang Q., Shi S., Liu Y., Uyanne J., Shi Y., Shi S., et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 2009, 183:7787-7798.
42. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 2006, 177:2080-2087.
43. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
44. Liu Y., Yin Z., Zhang R., Yan K., Chen L., Chen F., et al. MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6. Biochem. Biophys. Res. Commun. 2014, 450:1409-1415.
45. Du Rocher B., Mencalha A.L., Gomes B.E., Abdelhay E. Mesenchymal stromal cells impair the differentiation of CD14(++) CD16(-) CD64(+) classical monocytes into CD14(++) CD16(+) CD64(++) activate monocytes. Cytotherapy 2012, 14:12-25.
46. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
47. Hanada T., Yoshida H., Kato S., Tanaka K., Masutani K., Tsukada J., et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003, 19:437-450.
48. Deng Y., Yi S., Wang G., Cheng J., Zhang Y., Chen W., et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 2014, 23:2080-2092.
49. Zhang B., Liu R., Shi D., Liu X., Chen Y., Dou X., et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009, 113:46-57.
50. Yin B., Ma G., Yen C.Y., Zhou Z., Wang G.X., Divino C.M., et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J. Immunol. 2010, 185:5828-5834.
51. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176:284-290.
52. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
53. Chen H.W., Chen H.Y., Wang L.T., Wang F.H., Fang L.W., Lai H.Y., et al. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J. Immunol. 2013, 190:5065-5077.
54. Yen B.L., Yen M.L., Hsu P.J., Liu K.J., Wang C.J., Bai C.H., et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Reports 2013, 1:139-151.
55. Hung S.C., Pochampally R.R., Chen S.C., Hsu S.C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370.
56. Rees A.J. Monocyte and macrophage biology: an overview. Semin. Nephrol. 2010, 30:216-233.
57. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009, 27:669-692.
58. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008, 3:e1886.
59. Chen P.M., Liu K.J., Hsu P.J., Wei C.F., Bai C.H., Ho L.J., et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2. J. Leukoc. Biol. 2014, 96:295-303.
60. Gao S., Mao F., Zhang B., Zhang L., Zhang X., Wang M., et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-kappaB and signal transducer and activator of transcription 3 pathways. Exp. Biol. Med. 2014, 239:366-375.
61. Zhang Q.Z., Su W.R., Shi S.H., Wilder-Smith P., Xiang A.P., Wong A., et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 2010, 28:1856-1868.
62. Zanier E.R., Pischiutta F., Riganti L., Marchesi F., Turola E., Fumagalli S., et al. Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics 2014, 11:679-695.
63. Melief S.M., Schrama E., Brugman M.H., Tiemessen M.M., Hoogduijn M.J., Fibbe W.E., et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013, 31:1980-1991.
64. Francois M., Romieu-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Therapy 2012, 20:187-195.
65. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15:42-49.
66. Cutler A.J., Limbani V., Girdlestone J., Navarrete C.V. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J. Immunol. 2010, 185:6617-6623.
67. Caplan A.I., The Correa D. MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
68. Gupta N., Krasnodembskaya A., Kapetanaki M., Mouded M., Tan X., Serikov V., et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012, 67:533-539.
69. Gupta N., Su X., Popov B., Lee J.W., Serikov V., Matthay M.A. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J. Immunol. 2007, 179:1855-1863.